After binding a cell, an antibody drug may be taken inside, recycled or processed. These movements affect how much active drug reaches the place where it acts.
A quantitative study of a trastuzumab-maytansinoid conjugate separated surface binding, internalization, degradation, payload movement and intracellular binding. It found that processing rates influenced delivered payload in the studied cell lines. Surface staining or uptake alone does not establish release of an active species at its intracellular target. The relevant processing steps depend on the construct and its linker-payload chemistry.
Showing the technology this term belongs to: Antibody-drug conjugate (ADC).
Shares Antigen expression and treatment response, Evidence from measurement to patient benefit, Antibody-drug conjugate (ADC).
Shares Drug target engagement, Evidence from measurement to patient benefit.
Shares Drug target engagement, Evidence from measurement to patient benefit.
Shares Antigen expression and treatment response, Evidence from measurement to patient benefit.
Shares Drug target engagement, Evidence from measurement to patient benefit.
Shares Lysosomal payload transport, Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/